7 assets in CHEK2-Related Cancer Predisposition

Therapeutic assets addressing CHEK2-Related Cancer Predisposition, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Abiraterone CHEK2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Docetaxel CHEK2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Exemestane CHEK2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)
Niraparib CHEK2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Olaparib CHEK2-Related Cancer Predisposition	Beth Israel Deaconess Medical Center	P2	CCC (53)
Prednisone CHEK2-Related Cancer Predisposition	Qian Qin	P2	CCC (53)
Tamoxifen CHEK2-Related Cancer Predisposition	Dana-Farber Cancer Institute	P2	CCC (53)